Thus, our study fills an important gap by elucidating a previously underestimated mechanism of EGFR post-translational regulation and proposing targeted EGFR degradation as a means to improve therapeutic outcomes in drug-resistant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.